Clinical significance of circulating galectins as colorectal cancer markers

Watanabe Makoto, Takemasa Ichiro, Kaneko Naoki, Yokoyama Yuhki, Ei Ichi Matsuo, Iwasa Susumu, Mori Masaki, Matsuura Nariaki, Monden Morito, Nishimura Osamu

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The utility of CEA and CA 19-9 as colorectal carcinoma (CRC) markers is limited and development of additional reliable markers is under investigation. We previously showed that galectin-1 is overexpressed in CRC tissues. If such a protein leaks into the peripheral circulation, it might constitute a tumor marker candidate. Here, we test the hypothesis that the levels of circulating galectins could reflect the presence of CRC and/or its progression state. We constructed sandwich ELISAs for galectin-1/-2/-3/-4/-7 and determined their plasma concentrations in 105 CRC patients and 100 healthy volunteers (control). Matched pair samples of 56 patients pre- and post-surgery were also subjected to ELISA analysis. Circulating levels of galectin-1/-3/-4 in CRC patients were significantly higher compared to those in controls. Galectin-1 and galectin-4 levels significantly decreased after surgery (P<0.01), and the level of galectin-4 in most patients fell below the cut-off value. The levels of circulating galectin-4 significantly increased as the tumor stage progressed (P<0.001), whereas those for galectin-1 were relatively high from an early stage. Combined use of galectin-4 with CEA and/or CA19-9 markedly increased the proportion of CRC patients who were positive for tumor markers (from 33.3 to 59.0% for CEA and from 17.1 to 51.4% for CA 19-9). Our data show that galectin-4 may be a tumor marker for use in patient follow-up, while galectin-1 could be used for tumor screening. In particular, galectin-4 can be useful as a complementary marker when combined with CEA/CA19-9 to improve CRC follow-up.

Original languageEnglish
Pages (from-to)1217-1226
Number of pages10
JournalOncology reports
Volume25
Issue number5
DOIs
Publication statusPublished - May 1 2011
Externally publishedYes

Fingerprint

Galectin 4
Galectins
Galectin 1
Colorectal Neoplasms
Tumor Biomarkers
Galectin 2
Enzyme-Linked Immunosorbent Assay
Galectin 3
Neoplasms
Healthy Volunteers

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Makoto, W., Ichiro, T., Naoki, K., Yuhki, Y., Matsuo, E. I., Susumu, I., ... Osamu, N. (2011). Clinical significance of circulating galectins as colorectal cancer markers. Oncology reports, 25(5), 1217-1226. https://doi.org/10.3892/or.2011.1198

Clinical significance of circulating galectins as colorectal cancer markers. / Makoto, Watanabe; Ichiro, Takemasa; Naoki, Kaneko; Yuhki, Yokoyama; Matsuo, Ei Ichi; Susumu, Iwasa; Masaki, Mori; Nariaki, Matsuura; Morito, Monden; Osamu, Nishimura.

In: Oncology reports, Vol. 25, No. 5, 01.05.2011, p. 1217-1226.

Research output: Contribution to journalArticle

Makoto, W, Ichiro, T, Naoki, K, Yuhki, Y, Matsuo, EI, Susumu, I, Masaki, M, Nariaki, M, Morito, M & Osamu, N 2011, 'Clinical significance of circulating galectins as colorectal cancer markers', Oncology reports, vol. 25, no. 5, pp. 1217-1226. https://doi.org/10.3892/or.2011.1198
Makoto W, Ichiro T, Naoki K, Yuhki Y, Matsuo EI, Susumu I et al. Clinical significance of circulating galectins as colorectal cancer markers. Oncology reports. 2011 May 1;25(5):1217-1226. https://doi.org/10.3892/or.2011.1198
Makoto, Watanabe ; Ichiro, Takemasa ; Naoki, Kaneko ; Yuhki, Yokoyama ; Matsuo, Ei Ichi ; Susumu, Iwasa ; Masaki, Mori ; Nariaki, Matsuura ; Morito, Monden ; Osamu, Nishimura. / Clinical significance of circulating galectins as colorectal cancer markers. In: Oncology reports. 2011 ; Vol. 25, No. 5. pp. 1217-1226.
@article{e860ab597c0b4a40bf0335bc185b06c3,
title = "Clinical significance of circulating galectins as colorectal cancer markers",
abstract = "The utility of CEA and CA 19-9 as colorectal carcinoma (CRC) markers is limited and development of additional reliable markers is under investigation. We previously showed that galectin-1 is overexpressed in CRC tissues. If such a protein leaks into the peripheral circulation, it might constitute a tumor marker candidate. Here, we test the hypothesis that the levels of circulating galectins could reflect the presence of CRC and/or its progression state. We constructed sandwich ELISAs for galectin-1/-2/-3/-4/-7 and determined their plasma concentrations in 105 CRC patients and 100 healthy volunteers (control). Matched pair samples of 56 patients pre- and post-surgery were also subjected to ELISA analysis. Circulating levels of galectin-1/-3/-4 in CRC patients were significantly higher compared to those in controls. Galectin-1 and galectin-4 levels significantly decreased after surgery (P<0.01), and the level of galectin-4 in most patients fell below the cut-off value. The levels of circulating galectin-4 significantly increased as the tumor stage progressed (P<0.001), whereas those for galectin-1 were relatively high from an early stage. Combined use of galectin-4 with CEA and/or CA19-9 markedly increased the proportion of CRC patients who were positive for tumor markers (from 33.3 to 59.0{\%} for CEA and from 17.1 to 51.4{\%} for CA 19-9). Our data show that galectin-4 may be a tumor marker for use in patient follow-up, while galectin-1 could be used for tumor screening. In particular, galectin-4 can be useful as a complementary marker when combined with CEA/CA19-9 to improve CRC follow-up.",
author = "Watanabe Makoto and Takemasa Ichiro and Kaneko Naoki and Yokoyama Yuhki and Matsuo, {Ei Ichi} and Iwasa Susumu and Mori Masaki and Matsuura Nariaki and Monden Morito and Nishimura Osamu",
year = "2011",
month = "5",
day = "1",
doi = "10.3892/or.2011.1198",
language = "English",
volume = "25",
pages = "1217--1226",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Clinical significance of circulating galectins as colorectal cancer markers

AU - Makoto, Watanabe

AU - Ichiro, Takemasa

AU - Naoki, Kaneko

AU - Yuhki, Yokoyama

AU - Matsuo, Ei Ichi

AU - Susumu, Iwasa

AU - Masaki, Mori

AU - Nariaki, Matsuura

AU - Morito, Monden

AU - Osamu, Nishimura

PY - 2011/5/1

Y1 - 2011/5/1

N2 - The utility of CEA and CA 19-9 as colorectal carcinoma (CRC) markers is limited and development of additional reliable markers is under investigation. We previously showed that galectin-1 is overexpressed in CRC tissues. If such a protein leaks into the peripheral circulation, it might constitute a tumor marker candidate. Here, we test the hypothesis that the levels of circulating galectins could reflect the presence of CRC and/or its progression state. We constructed sandwich ELISAs for galectin-1/-2/-3/-4/-7 and determined their plasma concentrations in 105 CRC patients and 100 healthy volunteers (control). Matched pair samples of 56 patients pre- and post-surgery were also subjected to ELISA analysis. Circulating levels of galectin-1/-3/-4 in CRC patients were significantly higher compared to those in controls. Galectin-1 and galectin-4 levels significantly decreased after surgery (P<0.01), and the level of galectin-4 in most patients fell below the cut-off value. The levels of circulating galectin-4 significantly increased as the tumor stage progressed (P<0.001), whereas those for galectin-1 were relatively high from an early stage. Combined use of galectin-4 with CEA and/or CA19-9 markedly increased the proportion of CRC patients who were positive for tumor markers (from 33.3 to 59.0% for CEA and from 17.1 to 51.4% for CA 19-9). Our data show that galectin-4 may be a tumor marker for use in patient follow-up, while galectin-1 could be used for tumor screening. In particular, galectin-4 can be useful as a complementary marker when combined with CEA/CA19-9 to improve CRC follow-up.

AB - The utility of CEA and CA 19-9 as colorectal carcinoma (CRC) markers is limited and development of additional reliable markers is under investigation. We previously showed that galectin-1 is overexpressed in CRC tissues. If such a protein leaks into the peripheral circulation, it might constitute a tumor marker candidate. Here, we test the hypothesis that the levels of circulating galectins could reflect the presence of CRC and/or its progression state. We constructed sandwich ELISAs for galectin-1/-2/-3/-4/-7 and determined their plasma concentrations in 105 CRC patients and 100 healthy volunteers (control). Matched pair samples of 56 patients pre- and post-surgery were also subjected to ELISA analysis. Circulating levels of galectin-1/-3/-4 in CRC patients were significantly higher compared to those in controls. Galectin-1 and galectin-4 levels significantly decreased after surgery (P<0.01), and the level of galectin-4 in most patients fell below the cut-off value. The levels of circulating galectin-4 significantly increased as the tumor stage progressed (P<0.001), whereas those for galectin-1 were relatively high from an early stage. Combined use of galectin-4 with CEA and/or CA19-9 markedly increased the proportion of CRC patients who were positive for tumor markers (from 33.3 to 59.0% for CEA and from 17.1 to 51.4% for CA 19-9). Our data show that galectin-4 may be a tumor marker for use in patient follow-up, while galectin-1 could be used for tumor screening. In particular, galectin-4 can be useful as a complementary marker when combined with CEA/CA19-9 to improve CRC follow-up.

UR - http://www.scopus.com/inward/record.url?scp=79953043430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953043430&partnerID=8YFLogxK

U2 - 10.3892/or.2011.1198

DO - 10.3892/or.2011.1198

M3 - Article

C2 - 21369702

AN - SCOPUS:79953043430

VL - 25

SP - 1217

EP - 1226

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -